+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Antiangiogenic Drugs Market - Global Forecast 2026-2032- Product Image
Antiangiogenic Drugs Market - Global Forecast 2026-2032- Product Image
Sale

Antiangiogenic Drugs Market - Global Forecast 2026-2032

  • Report

  • 193 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6150938
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Antiangiogenic Drugs Market is projected to reach USD 16.66 Billion in 2026. It is expected to continue growing at a CAGR of 5.37%, reaching USD 22.81 Billion by 2032.

Antiangiogenic Drugs: Executive Summary

Antiangiogenic drugs inhibit the formation of new blood vessels and are used across oncology and selected ophthalmic conditions. Their role is shaped by clinical evidence, treatment-line positioning, biomarker development, safety management, reimbursement policy, and delivery convenience. The landscape includes antibody therapies, kinase inhibitors, fusion proteins, and other agents administered systemically or locally, with adoption varying substantially by indication and healthcare system.

Clinical Expansion and Treatment-Design Shifts

The field is moving from broad angiogenesis inhibition toward more selective treatment design and combination regimens. Clinical development increasingly evaluates antiangiogenic agents alongside immune checkpoint inhibitors, chemotherapy, targeted therapies, and radiotherapy, while ophthalmic practice emphasizes disease-specific dosing intervals and durable control. Biosimilar availability, real-world evidence, companion diagnostics, and efforts to reduce treatment burden are also influencing prescribing and access decisions.

Artificial Intelligence Is Strengthening Discovery and Care Pathways

Artificial intelligence is contributing to target identification, molecular screening, trial recruitment, imaging analysis, and outcome prediction. In ophthalmology, image-based models can support lesion detection, activity assessment, and injection-interval planning, although clinical validation and workflow integration remain essential. In oncology, AI may help identify response patterns and toxicity risks, but inconsistent data quality, limited interpretability, privacy requirements, and regulatory oversight constrain rapid deployment.

Regional Insights: Different Access and Evidence Environments

North America combines advanced clinical infrastructure with strong specialty-care capacity, while Latin America faces greater variation in reimbursement, diagnostic access, and treatment continuity. Europe benefits from coordinated regulatory and health-technology-assessment processes, yet country-level funding decisions differ. Middle Eastern access is concentrated in better-resourced systems, and African markets remain strongly influenced by affordability, diagnostic capacity, and specialist availability. Asia-Pacific presents broad clinical opportunity alongside pronounced differences in healthcare investment, biosimilar uptake, and rural access.

Group Insights: Policy Alignment Shapes Adoption

ASEAN markets reflect diverse regulatory pathways, procurement systems, and specialist capacity, making regional harmonization valuable. BRICS countries combine substantial research and manufacturing capabilities with uneven access and healthcare infrastructure. The European Union is influenced by centralized scientific assessment alongside national reimbursement decisions. G7 systems generally support sophisticated clinical research and pharmacovigilance, while GCC countries are expanding specialized care capacity. NATO members remain diverse, but shared attention to resilient supply chains and health-system preparedness can affect procurement priorities.

Country Insights: Varied Priorities Across Leading Markets

The United States and Canada emphasize specialty care, evidence generation, and payer-management considerations. Brazil and Mexico face regional disparities in diagnosis, reimbursement, and continuity of care. France, Germany, Italy, Spain, and the United Kingdom balance clinical innovation with formal assessment, budget management, and public-system access requirements. China and India are expanding treatment capacity while addressing affordability, domestic production, and geographic variation. Japan and South Korea combine advanced hospitals with aging-population needs and structured reimbursement systems. Australia focuses on specialist access, public funding pathways, and care delivery across dispersed communities. Russia’s access environment is shaped by procurement, domestic supply considerations, and uneven regional capacity.

Priorities for Leaders: Improve Evidence, Access, and Delivery

Industry leaders should prioritize indication-specific evidence that connects clinical outcomes with quality of life, treatment burden, and resource use. They should develop combination strategies with clearly defined patient-selection criteria, strengthen post-market safety monitoring, and support validated biomarkers and imaging tools. Access plans should address affordability, local regulatory requirements, cold-chain or administration needs, and specialist shortages. Responsible AI adoption requires representative datasets, transparent validation, human oversight, cybersecurity controls, and measurable impact on patient care.

Methodology: Evidence-Led Market Assessment

This executive summary uses a structured review of the antiangiogenic-drug landscape, focusing on therapeutic mechanisms, clinical-use patterns, development priorities, healthcare-system factors, regional conditions, and technology trends. Findings are synthesized from publicly verifiable categories of evidence, including peer-reviewed research, regulatory materials, clinical-trial records, treatment guidelines, health-technology assessments, and institutional reports. Interpretations are presented qualitatively and avoid market estimates, market sizing, market shares, and forecasts.

Conclusion: Sustaining Value Through Precision and Access

Antiangiogenic drugs remain important tools in oncology and ophthalmology, but future value will depend on more than pharmacologic activity. Durable progress requires better patient selection, evidence-based combinations, safer and more convenient delivery, reliable diagnostics, and equitable access. Regional policy differences and uneven healthcare capacity make locally adapted strategies essential, while validated AI applications may improve development and care when deployed with rigorous clinical governance.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Antiangiogenic Drugs Market, by Molecule Type
7.1. Introduction
7.2. Monoclonal Antibody
7.3. Peptide
7.4. Small Molecule
8. Antiangiogenic Drugs Market, by Mechanism Of Action
8.1. Introduction
8.2. Integrin Inhibitor
8.3. Tyrosine Kinase Inhibitor
8.4. Vascular Endothelial Growth Factor Inhibitor
9. Antiangiogenic Drugs Market, by Indication
9.1. Introduction
9.2. Age-Related Macular Degeneration
9.2.1. Dry AMD
9.2.2. Wet AMD
9.3. Cancer
9.3.1. Colorectal Cancer
9.3.2. Hepatocellular Carcinoma
9.3.3. Lung Cancer
9.3.4. Renal Cell Carcinoma
9.4. Diabetic Retinopathy
9.4.1. Non-Proliferative
9.4.2. Proliferative
10. Antiangiogenic Drugs Market, by Route Of Administration
10.1. Introduction
10.2. Intravenous
10.3. Intravitreal Injection
10.4. Oral
10.5. Subcutaneous
11. Antiangiogenic Drugs Market, by End User
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Retail Pharmacy
11.4. Specialty Clinics
12. Antiangiogenic Drugs Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Antiangiogenic Drugs Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Antiangiogenic Drugs Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. AbbVie
16.2. Amgen Inc
16.3. AstraZeneca
16.4. Bayer AG
16.5. Bristol Myers Squibb
16.6. Celltrion USA Inc
16.7. Daiichi Sankyo Co. Ltd.
16.8. Eli Lilly and Company
16.9. F. Hoffmann-La Roche Ltd
16.10. Gilead Sciences Inc
16.11. GSK plc
16.12. Hutchmed Ltd
16.13. Johnson & Johnson
16.14. Merck & Co. Inc.
16.15. Novartis AG
16.16. Pfizer Inc.
16.17. Regeneron Pharmaceuticals Inc.
16.18. Sanofi S.A.
16.19. Seagen Inc
16.20. Sun Pharmaceutical Industries Ltd.
16.21. Takeda Pharmaceutical Company Limited
16.22. Teva Pharmaceutical Industries Ltd.
16.23. Viatris
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global Antiangiogenic Drugs Market, Years Considered for the Study
FIGURE 2. Global Antiangiogenic Drugs Market, Research Design
FIGURE 3. Global Antiangiogenic Drugs Market, Research Framework
FIGURE 4. Global Antiangiogenic Drugs Market, Data Triangulation
FIGURE 5. Global Antiangiogenic Drugs Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Antiangiogenic Drugs Market Size, by Molecule Type, 2025 vs 2032 (%)
FIGURE 7. Global Antiangiogenic Drugs Market Size, by Molecule Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Antiangiogenic Drugs Market Size, by Mechanism Of Action, 2025 vs 2032 (%)
FIGURE 9. Global Antiangiogenic Drugs Market Size, by Mechanism Of Action, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Antiangiogenic Drugs Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 11. Global Antiangiogenic Drugs Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Antiangiogenic Drugs Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 13. Global Antiangiogenic Drugs Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Antiangiogenic Drugs Market Size, by End User, 2025 vs 2032 (%)
FIGURE 15. Global Antiangiogenic Drugs Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Antiangiogenic Drugs Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Antiangiogenic Drugs Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Antiangiogenic Drugs Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Antiangiogenic Drugs Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Antiangiogenic Drugs Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Antiangiogenic Drugs Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Antiangiogenic Drugs Market Segmentation & Coverage
TABLE 2. Global Antiangiogenic Drugs Market Size, 2017-2032 (USD Million)
TABLE 3. Global Antiangiogenic Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 4. Global Monoclonal Antibody Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Monoclonal Antibody Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Monoclonal Antibody Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Peptide Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Peptide Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Peptide Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Small Molecule Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Small Molecule Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Small Molecule Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Antiangiogenic Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 14. Global Integrin Inhibitor Market Size, by Region, 2017-2032 (USD Million)
TABLE 15. Global Integrin Inhibitor Market Size, by Group, 2017-2032 (USD Million)
TABLE 16. Global Integrin Inhibitor Market Size, by Country, 2017-2032 (USD Million)
TABLE 17. Global Tyrosine Kinase Inhibitor Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Tyrosine Kinase Inhibitor Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Tyrosine Kinase Inhibitor Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Vascular Endothelial Growth Factor Inhibitor Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Vascular Endothelial Growth Factor Inhibitor Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Vascular Endothelial Growth Factor Inhibitor Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global Antiangiogenic Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 24. Global Age-Related Macular Degeneration Market Size, by Region, 2017-2032 (USD Million)
TABLE 25. Global Age-Related Macular Degeneration Market Size, by Group, 2017-2032 (USD Million)
TABLE 26. Global Age-Related Macular Degeneration Market Size, by Country, 2017-2032 (USD Million)
TABLE 27. Global Dry AMD Market Size, by Region, 2017-2032 (USD Million)
TABLE 28. Global Dry AMD Market Size, by Group, 2017-2032 (USD Million)
TABLE 29. Global Dry AMD Market Size, by Country, 2017-2032 (USD Million)
TABLE 30. Global Wet AMD Market Size, by Region, 2017-2032 (USD Million)
TABLE 31. Global Wet AMD Market Size, by Group, 2017-2032 (USD Million)
TABLE 32. Global Wet AMD Market Size, by Country, 2017-2032 (USD Million)
TABLE 33. Global Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 34. Global Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 35. Global Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 36. Global Colorectal Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 37. Global Colorectal Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 38. Global Colorectal Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 39. Global Hepatocellular Carcinoma Market Size, by Region, 2017-2032 (USD Million)
TABLE 40. Global Hepatocellular Carcinoma Market Size, by Group, 2017-2032 (USD Million)
TABLE 41. Global Hepatocellular Carcinoma Market Size, by Country, 2017-2032 (USD Million)
TABLE 42. Global Lung Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 43. Global Lung Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 44. Global Lung Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 45. Global Renal Cell Carcinoma Market Size, by Region, 2017-2032 (USD Million)
TABLE 46. Global Renal Cell Carcinoma Market Size, by Group, 2017-2032 (USD Million)
TABLE 47. Global Renal Cell Carcinoma Market Size, by Country, 2017-2032 (USD Million)
TABLE 48. Global Diabetic Retinopathy Market Size, by Region, 2017-2032 (USD Million)
TABLE 49. Global Diabetic Retinopathy Market Size, by Group, 2017-2032 (USD Million)
TABLE 50. Global Diabetic Retinopathy Market Size, by Country, 2017-2032 (USD Million)
TABLE 51. Global Non-Proliferative Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Global Non-Proliferative Market Size, by Group, 2017-2032 (USD Million)
TABLE 53. Global Non-Proliferative Market Size, by Country, 2017-2032 (USD Million)
TABLE 54. Global Proliferative Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Global Proliferative Market Size, by Group, 2017-2032 (USD Million)
TABLE 56. Global Proliferative Market Size, by Country, 2017-2032 (USD Million)
TABLE 57. Global Antiangiogenic Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 58. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
TABLE 59. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
TABLE 60. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
TABLE 61. Global Intravitreal Injection Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Global Intravitreal Injection Market Size, by Group, 2017-2032 (USD Million)
TABLE 63. Global Intravitreal Injection Market Size, by Country, 2017-2032 (USD Million)
TABLE 64. Global Oral Market Size, by Region, 2017-2032 (USD Million)
TABLE 65. Global Oral Market Size, by Group, 2017-2032 (USD Million)
TABLE 66. Global Oral Market Size, by Country, 2017-2032 (USD Million)
TABLE 67. Global Subcutaneous Market Size, by Region, 2017-2032 (USD Million)
TABLE 68. Global Subcutaneous Market Size, by Group, 2017-2032 (USD Million)
TABLE 69. Global Subcutaneous Market Size, by Country, 2017-2032 (USD Million)
TABLE 70. Global Antiangiogenic Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 71. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 72. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 73. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 74. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 75. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 76. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 77. Global Specialty Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 78. Global Specialty Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 79. Global Specialty Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 80. Global Antiangiogenic Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 81. Asia-Pacific Antiangiogenic Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 82. Asia-Pacific Antiangiogenic Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 83. Asia-Pacific Antiangiogenic Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 84. Asia-Pacific Antiangiogenic Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 85. Asia-Pacific Antiangiogenic Drugs Market Size, by Age-Related Macular Degeneration, 2017-2032 (USD Million)
TABLE 86. Asia-Pacific Antiangiogenic Drugs Market Size, by Cancer, 2017-2032 (USD Million)
TABLE 87. Asia-Pacific Antiangiogenic Drugs Market Size, by Diabetic Retinopathy, 2017-2032 (USD Million)
TABLE 88. Asia-Pacific Antiangiogenic Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 89. Asia-Pacific Antiangiogenic Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 90. North America Antiangiogenic Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 91. North America Antiangiogenic Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 92. North America Antiangiogenic Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 93. North America Antiangiogenic Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 94. North America Antiangiogenic Drugs Market Size, by Age-Related Macular Degeneration, 2017-2032 (USD Million)
TABLE 95. North America Antiangiogenic Drugs Market Size, by Cancer, 2017-2032 (USD Million)
TABLE 96. North America Antiangiogenic Drugs Market Size, by Diabetic Retinopathy, 2017-2032 (USD Million)
TABLE 97. North America Antiangiogenic Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 98. North America Antiangiogenic Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 99. Latin America Antiangiogenic Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 100. Latin America Antiangiogenic Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 101. Latin America Antiangiogenic Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 102. Latin America Antiangiogenic Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 103. Latin America Antiangiogenic Drugs Market Size, by Age-Related Macular Degeneration, 2017-2032 (USD Million)
TABLE 104. Latin America Antiangiogenic Drugs Market Size, by Cancer, 2017-2032 (USD Million)
TABLE 105. Latin America Antiangiogenic Drugs Market Size, by Diabetic Retinopathy, 2017-2032 (USD Million)
TABLE 106. Latin America Antiangiogenic Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 107. Latin America Antiangiogenic Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 108. Europe Antiangiogenic Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 109. Europe Antiangiogenic Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 110. Europe Antiangiogenic Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 111. Europe Antiangiogenic Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 112. Europe Antiangiogenic Drugs Market Size, by Age-Related Macular Degeneration, 2017-2032 (USD Million)
TABLE 113. Europe Antiangiogenic Drugs Market Size, by Cancer, 2017-2032 (USD Million)
TABLE 114. Europe Antiangiogenic Drugs Market Size, by Diabetic Retinopathy, 2017-2032 (USD Million)
TABLE 115. Europe Antiangiogenic Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 116. Europe Antiangiogenic Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 117. Middle East Antiangiogenic Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 118. Middle East Antiangiogenic Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 119. Middle East Antiangiogenic Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 120. Middle East Antiangiogenic Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 121. Middle East Antiangiogenic Drugs Market Size, by Age-Related Macular Degeneration, 2017-2032 (USD Million)
TABLE 122. Middle East Antiangiogenic Drugs Market Size, by Cancer, 2017-2032 (USD Million)
TABLE 123. Middle East Antiangiogenic Drugs Market Size, by Diabetic Retinopathy, 2017-2032 (USD Million)
TABLE 124. Middle East Antiangiogenic Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 125. Middle East Antiangiogenic Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 126. Africa Antiangiogenic Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 127. Africa Antiangiogenic Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 128. Africa Antiangiogenic Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 129. Africa Antiangiogenic Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 130. Africa Antiangiogenic Drugs Market Size, by Age-Related Macular Degeneration, 2017-2032 (USD Million)
TABLE 131. Africa Antiangiogenic Drugs Market Size, by Cancer, 2017-2032 (USD Million)
TABLE 132. Africa Antiangiogenic Drugs Market Size, by Diabetic Retinopathy, 2017-2032 (USD Million)
TABLE 133. Africa Antiangiogenic Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 134. Africa Antiangiogenic Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 135. Global Antiangiogenic Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 136. ASEAN Antiangiogenic Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 137. ASEAN Antiangiogenic Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 138. ASEAN Antiangiogenic Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 139. ASEAN Antiangiogenic Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 140. ASEAN Antiangiogenic Drugs Market Size, by Age-Related Macular Degeneration, 2017-2032 (USD Million)
TABLE 141. ASEAN Antiangiogenic Drugs Market Size, by Cancer, 2017-2032 (USD Million)
TABLE 142. ASEAN Antiangiogenic Drugs Market Size, by Diabetic Retinopathy, 2017-2032 (USD Million)
TABLE 143. ASEAN Antiangiogenic Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 144. ASEAN Antiangiogenic Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 145. GCC Antiangiogenic Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 146. GCC Antiangiogenic Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 147. GCC Antiangiogenic Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 148. GCC Antiangiogenic Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 149. GCC Antiangiogenic Drugs Market Size, by Age-Related Macular Degeneration, 2017-2032 (USD Million)
TABLE 150. GCC Antiangiogenic Drugs Market Size, by Cancer, 2017-2032 (USD Million)
TABLE 151. GCC Antiangiogenic Drugs Market Size, by Diabetic Retinopathy, 2017-2032 (USD Million)
TABLE 152. GCC Antiangiogenic Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 153. GCC Antiangiogenic Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 154. European Union Antiangiogenic Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 155. European Union Antiangiogenic Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 156. European Union Antiangiogenic Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 157. European Union Antiangiogenic Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 158. European Union Antiangiogenic Drugs Market Size, by Age-Related Macular Degeneration, 2017-2032 (USD Million)
TABLE 159. European Union Antiangiogenic Drugs Market Size, by Cancer, 2017-2032 (USD Million)
TABLE 160. European Union Antiangiogenic Drugs Market Size, by Diabetic Retinopathy, 2017-2032 (USD Million)
TABLE 161. European Union Antiangiogenic Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 162. European Union Antiangiogenic Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 163. BRICS Antiangiogenic Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 164. BRICS Antiangiogenic Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 165. BRICS Antiangiogenic Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 166. BRICS Antiangiogenic Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 167. BRICS Antiangiogenic Drugs Market Size, by Age-Related Macular Degeneration, 2017-2032 (USD Million)
TABLE 168. BRICS Antiangiogenic Drugs Market Size, by Cancer, 2017-2032 (USD Million)
TABLE 169. BRICS Antiangiogenic Drugs Market Size, by Diabetic Retinopathy, 2017-2032 (USD Million)
TABLE 170. BRICS Antiangiogenic Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 171. BRICS Antiangiogenic Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 172. G7 Antiangiogenic Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 173. G7 Antiangiogenic Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 174. G7 Antiangiogenic Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 175. G7 Antiangiogenic Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 176. G7 Antiangiogenic Drugs Market Size, by Age-Related Macular Degeneration, 2017-2032 (USD Million)
TABLE 177. G7 Antiangiogenic Drugs Market Size, by Cancer, 2017-2032 (USD Million)
TABLE 178. G7 Antiangiogenic Drugs Market Size, by Diabetic Retinopathy, 2017-2032 (USD Million)
TABLE 179. G7 Antiangiogenic Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 180. G7 Antiangiogenic Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 181. NATO Antiangiogenic Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 182. NATO Antiangiogenic Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 183. NATO Antiangiogenic Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 184. NATO Antiangiogenic Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 185. NATO Antiangiogenic Drugs Market Size, by Age-Related Macular Degeneration, 2017-2032 (USD Million)
TABLE 186. NATO Antiangiogenic Drugs Market Size, by Cancer, 2017-2032 (USD Million)
TABLE 187. NATO Antiangiogenic Drugs Market Size, by Diabetic Retinopathy, 2017-2032 (USD Million)
TABLE 188. NATO Antiangiogenic Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 189. NATO Antiangiogenic Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 190. Global Antiangiogenic Drugs Market Size, by Country, 2017-2032 (USD Million)
TABLE 191. United States Antiangiogenic Drugs Market Size, 2017-2032 (USD Million)
TABLE 192. United States Antiangiogenic Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 193. United States Antiangiogenic Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 194. United States Antiangiogenic Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 195. United States Antiangiogenic Drugs Market Size, by Age-Related Macular Degeneration, 2017-2032 (USD Million)
TABLE 196. United States Antiangiogenic Drugs Market Size, by Cancer, 2017-2032 (USD Million)
TABLE 197. United States Antiangiogenic Drugs Market Size, by Diabetic Retinopathy, 2017-2032 (USD Million)
TABLE 198. United States Antiangiogenic Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 199. United States Antiangiogenic Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 200. Canada Antiangiogenic Drugs Market Size, 2017-2032 (USD Million)
TABLE 201. Canada Antiangiogenic Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 202. Canada Antiangiogenic Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 203. Canada Antiangiogenic Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 204. Canada Antiangiogenic Drugs Market Size, by Age-Related Macular Degeneration, 2017-2032 (USD Million)
TABLE 205. Canada Antiangiogenic Drugs Market Size, by Cancer, 2017-2032 (USD Million)
TABLE 206. Canada Antiangiogenic Drugs Market Size, by Diabetic Retinopathy, 2017-2032 (USD Million)
TABLE 207. Canada Antiangiogenic Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 208. Canada Antiangiogenic Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 209. Mexico Antiangiogenic Drugs Market Size, 2017-2032 (USD Million)
TABLE 210. Mexico Antiangiogenic Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 211. Mexico Antiangiogenic Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 212. Mexico Antiangiogenic Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 213. Mexico Antiangiogenic Drugs Market Size, by Age-Related Macular Degeneration, 2017-2032 (USD Million)
TABLE 214. Mexico Antiangiogenic Drugs Market Size, by Cancer, 2017-2032 (USD Million)
TABLE 215. Mexico Antiangiogenic Drugs Market Size, by Diabetic Retinopathy, 2017-2032 (USD Million)
TABLE 216. Mexico Antiangiogenic Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 217. Mexico Antiangiogenic Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 218. Brazil Antiangiogenic Drugs Market Size, 2017-2032 (USD Million)
TABLE 219. Brazil Antiangiogenic Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 220. Brazil Antiangiogenic Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 221. Brazil Antiangiogenic Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 222. Brazil Antiangiogenic Drugs Market Size, by Age-Related Macular Degeneration, 2017-2032 (USD Million)
TABLE 223. Brazil Antiangiogenic Drugs Market Size, by Cancer, 2017-2032 (USD Million)
TABLE 224. Brazil Antiangiogenic Drugs Market Size, by Diabetic Retinopathy, 2017-2032 (USD Million)
TABLE 225. Brazil Antiangiogenic Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 226. Brazil Antiangiogenic Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 227. United Kingdom Antiangiogenic Drugs Market Size, 2017-2032 (USD Million)
TABLE 228. United Kingdom Antiangiogenic Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 229. United Kingdom Antiangiogenic Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 230. United Kingdom Antiangiogenic Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 231. United Kingdom Antiangiogenic Drugs Market Size, by Age-Related Macular Degeneration, 2017-2032 (USD Million)
TABLE 232. United Kingdom Antiangiogenic Drugs Market Size, by Cancer, 2017-2032 (USD Million)
TABLE 233. United Kingdom Antiangiogenic Drugs Market Size, by Diabetic Retinopathy, 2017-2032 (USD Million)
TABLE 234. United Kingdom Antiangiogenic Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 235. United Kingdom Antiangiogenic Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 236. Germany Antiangiogenic Drugs Market Size, 2017-2032 (USD Million)
TABLE 237. Germany Antiangiogenic Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 238. Germany Antiangiogenic Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 239. Germany Antiangiogenic Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 240. Germany Antiangiogenic Drugs Market Size, by Age-Related Macular Degeneration, 2017-2032 (USD Million)
TABLE 241. Germany Antiangiogenic Drugs Market Size, by Cancer, 2017-2032 (USD Million)
TABLE 242. Germany Antiangiogenic Drugs Market Size, by Diabetic Retinopathy, 2017-2032 (USD Million)
TABLE 243. Germany Antiangiogenic Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 244. Germany Antiangiogenic Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 245. France Antiangiogenic Drugs Market Size, 2017-2032 (USD Million)
TABLE 246. France Antiangiogenic Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 247. France Antiangiogenic Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 248. France Antiangiogenic Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 249. France Antiangiogenic Drugs Market Size, by Age-Related Macular Degeneration, 2017-2032 (USD Million)
TABLE 250. France Antiangiogenic Drugs Market Size, by Cancer, 2017-2032 (USD Million)
TABLE 251. France Antiangiogenic Drugs Market Size, by Diabetic Retinopathy, 2017-2032 (USD Million)
TABLE 252. France Antiangiogenic Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 253. France Antiangiogenic Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 254. Russia Antiangiogenic Drugs Market Size, 2017-2032 (USD Million)
TABLE 255. Russia Antiangiogenic Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 256. Russia Antiangiogenic Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 257. Russia Antiangiogenic Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 258. Russia Antiangiogenic Drugs Market Size, by Age-Related Macular Degeneration, 2017-2032 (USD Million)
TABLE 259. Russia Antiangiogenic Drugs Market Size, by Cancer, 2017-2032 (USD Million)
TABLE 260. Russia Antiangiogenic Drugs Market Size, by Diabetic Retinopathy, 2017-2032 (USD Million)
TABLE 261. Russia Antiangiogenic Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 262. Russia Antiangiogenic Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 263. Italy Antiangiogenic Drugs Market Size, 2017-2032 (USD Million)
TABLE 264. Italy Antiangiogenic Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 265. Italy Antiangiogenic Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 266. Italy Antiangiogenic Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 267. Italy Antiangiogenic Drugs Market Size, by Age-Related Macular Degeneration, 2017-2032 (USD Million)
TABLE 268. Italy Antiangiogenic Drugs Market Size, by Cancer, 2017-2032 (USD Million)
TABLE 269. Italy Antiangiogenic Drugs Market Size, by Diabetic Retinopathy, 2017-2032 (USD Million)
TABLE 270. Italy Antiangiogenic Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 271. Italy Antiangiogenic Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 272. Spain Antiangiogenic Drugs Market Size, 2017-2032 (USD Million)
TABLE 273. Spain Antiangiogenic Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 274. Spain Antiangiogenic Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 275. Spain Antiangiogenic Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 276. Spain Antiangiogenic Drugs Market Size, by Age-Related Macular Degeneration, 2017-2032 (USD Million)
TABLE 277. Spain Antiangiogenic Drugs Market Size, by Cancer, 2017-2032 (USD Million)
TABLE 278. Spain Antiangiogenic Drugs Market Size, by Diabetic Retinopathy, 2017-2032 (USD Million)
TABLE 279. Spain Antiangiogenic Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 280. Spain Antiangiogenic Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 281. China Antiangiogenic Drugs Market Size, 2017-2032 (USD Million)
TABLE 282. China Antiangiogenic Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 283. China Antiangiogenic Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 284. China Antiangiogenic Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 285. China Antiangiogenic Drugs Market Size, by Age-Related Macular Degeneration, 2017-2032 (USD Million)
TABLE 286. China Antiangiogenic Drugs Market Size, by Cancer, 2017-2032 (USD Million)
TABLE 287. China Antiangiogenic Drugs Market Size, by Diabetic Retinopathy, 2017-2032 (USD Million)
TABLE 288. China Antiangiogenic Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 289. China Antiangiogenic Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 290. India Antiangiogenic Drugs Market Size, 2017-2032 (USD Million)
TABLE 291. India Antiangiogenic Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 292. India Antiangiogenic Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 293. India Antiangiogenic Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 294. India Antiangiogenic Drugs Market Size, by Age-Related Macular Degeneration, 2017-2032 (USD Million)
TABLE 295. India Antiangiogenic Drugs Market Size, by Cancer, 2017-2032 (USD Million)
TABLE 296. India Antiangiogenic Drugs Market Size, by Diabetic Retinopathy, 2017-2032 (USD Million)
TABLE 297. India Antiangiogenic Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 298. India Antiangiogenic Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 299. Japan Antiangiogenic Drugs Market Size, 2017-2032 (USD Million)
TABLE 300. Japan Antiangiogenic Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 301. Japan Antiangiogenic Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 302. Japan Antiangiogenic Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 303. Japan Antiangiogenic Drugs Market Size, by Age-Related Macular Degeneration, 2017-2032 (USD Million)
TABLE 304. Japan Antiangiogenic Drugs Market Size, by Cancer, 2017-2032 (USD Million)
TABLE 305. Japan Antiangiogenic Drugs Market Size, by Diabetic Retinopathy, 2017-2032 (USD Million)
TABLE 306. Japan Antiangiogenic Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 307. Japan Antiangiogenic Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 308. Australia Antiangiogenic Drugs Market Size, 2017-2032 (USD Million)
TABLE 309. Australia Antiangiogenic Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 310. Australia Antiangiogenic Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 311. Australia Antiangiogenic Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 312. Australia Antiangiogenic Drugs Market Size, by Age-Related Macular Degeneration, 2017-2032 (USD Million)
TABLE 313. Australia Antiangiogenic Drugs Market Size, by Cancer, 2017-2032 (USD Million)
TABLE 314. Australia Antiangiogenic Drugs Market Size, by Diabetic Retinopathy, 2017-2032 (USD Million)
TABLE 315. Australia Antiangiogenic Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 316. Australia Antiangiogenic Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 317. South Korea Antiangiogenic Drugs Market Size, 2017-2032 (USD Million)
TABLE 318. South Korea Antiangiogenic Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 319. South Korea Antiangiogenic Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 320. South Korea Antiangiogenic Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 321. South Korea Antiangiogenic Drugs Market Size, by Age-Related Macular Degeneration, 2017-2032 (USD Million)
TABLE 322. South Korea Antiangiogenic Drugs Market Size, by Cancer, 2017-2032 (USD Million)
TABLE 323. South Korea Antiangiogenic Drugs Market Size, by Diabetic Retinopathy, 2017-2032 (USD Million)
TABLE 324. South Korea Antiangiogenic Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 325. South Korea Antiangiogenic Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 326. Global Antiangiogenic Drugs Market Share, by Key Player, 2025
TABLE 327. Global Antiangiogenic Drugs Market, Key Experts

Companies Mentioned

  • AbbVie
  • Amgen Inc
  • AstraZeneca
  • Bayer AG
  • Bristol Myers Squibb
  • Celltrion USA Inc
  • Daiichi Sankyo Co. Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences Inc
  • GSK plc
  • Hutchmed Ltd
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Sanofi S.A.
  • Seagen Inc
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris

Related Topics

Related Reports

Diabetic Retinopathy - Market Insight, Epidemiology, and Market Forecast - 2036 - Product Image

Diabetic Retinopathy - Market Insight, Epidemiology, and Market Forecast - 2036

  • Report
  • 171 Pages
  • Global
From
Elamipretide Sales Forecast and Market Size Analysis - 2034 - Product Image

Elamipretide Sales Forecast and Market Size Analysis - 2034

  • Report
  • 30 Pages
  • Global
From
Melanocortin Receptor Agonist Drugs Market - Global Forecast 2026-2032 - Product Image

Melanocortin Receptor Agonist Drugs Market - Global Forecast 2026-2032

  • Report
  • 187 Pages
  • Global
From
Diabetic Retinopathy Treatment - Global Strategic Business Report - Product Image

Diabetic Retinopathy Treatment - Global Strategic Business Report

  • Report
  • 273 Pages
  • Global
From
Enzyme Replacement Therapy Drugs for Gaucher Disease Market - Global Forecast 2026-2032 - Product Image

Enzyme Replacement Therapy Drugs for Gaucher Disease Market - Global Forecast 2026-2032

  • Report
  • 193 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.